Physician profile
Alex E Lechin
NPI 1790710895
$10,008.39
in general payments reported to CMS, 2019-2025
44 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,214 · 2021: $1,456 · 2022: $1,407 · 2023: $1,418 · 2024: $1,350 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,141.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,302.50 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $854.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $819.86 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $735.01 | 2019-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.20 | 2019-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $676.28 | 2021-2025 | Dupixent |
| Harmony Biosciences LLC | $485.56 | 2020-2025 | Wakix |
| Philips North America LLC | $461.78 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Mylan Specialty L.P. | $460.89 | 2019-2023 | Yupelri |
| Mallinckrodt Hospital Products INC. | $451.11 | 2020-2025 | Acthar |
| United Therapeutics Corporation | $356.36 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $172.71 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $162.39 | 2019-2025 | |
| Electromed, INC. | $148.82 | 2022-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $118.66 | 2021-2025 | Winrevair |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Lechin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.